<DOC>
	<DOCNO>NCT00346762</DOCNO>
	<brief_summary>HIV infect former commercial blood donor ( FBDs ) Fuyang , Anhui Province , China infect HIV common-source exposure contaminate blood . The purpose study examine role host viral factor HIV disease progression unique HIV infect population .</brief_summary>
	<brief_title>Evaluating Host Viral Factors Among HIV Infected Former Commercial Blood Donors Fuyang , Anhui Province , China</brief_title>
	<detailed_description>The HIV epidemic China reach phase exponential growth . Among infected FBDs rural community , become infected contaminate blood collection equipment . In Fuyang , Anhui Province , China , unregulated commercial blood collection occur 1992 1995 ; last decade , HIV infect FBDs progress AIDS , others long-term nonprogressors , require antiretroviral therapy ( ART ) . Since HIV infect participant study predict infect related HIV strain location infect , unique population study . It hypothesize host factor , host immunity genetic background , good predictor disease progression viral factor population . This study enroll HIV-1 infected FBDs age-matched HIV uninfected adult Fuyang , Anhui Province , China . There two stage study . Stage I cross-sectional study last 3 month . Participants HIV-1 infect FBDs age-matched HIV uninfected control . There two study visit Stage I ; 2-day screening/enrollment visit follow-up visit . On first day screening/enrollment , participant brief study ask complete demographic risk factor questionnaire ; medical medication history review physical examination also occur . All participant receive HIV prevention education risk reduction counseling ; additionally , HIV uninfected participant receive HIV pretest counseling . On second day screening , participant return clinic blood collection , females undergo pregnancy test . All participant return clinic receive laboratory result post-test counsel follow-up visit occur approximately 2 week screening/enrollment visit . Any participant CD4 count le 200 cells/mm3 meeting China Comprehensive AIDS Response ( CARES ) treatment criterion refer evaluation care . HIV infect FBD participant CD4 count 200 cells/mm3 invite enroll Stage II . Stage II longitudinal , prospective study last 19.5 month . Stage II enroll eligible HIV infect participant Stage I necessary , eligible patient refer China CARES . There least five study visit ; occur 2-day study screening/enrollment visit , follow-up visit 2 week screening/enrollment , Months 6 , 12 , 18 . Screening/enrollment follow-up visit procedure identical conduct Stage I . Visits Months 6 , 12 , 18 occur 2-day period . Medical medication history review physical examination occur first day ; participant need return clinic blood collection second day . Participants receive laboratory result post-test counsel next schedule study visit . Additional study visit may require participant experience clinically significant condition study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Stage I HIV Infected FBDs : Selfreported history blood donation 1995 HIV1 infect ART naive Willing provide locator information Willing use acceptable form contraception Inclusion Criteria Stage I HIV Uninfected Controls : HIV uninfected Willing provide locator information Willing undergo repeat HIV test Inclusion Criteria Stage II : Participant Stage I OR enrol directly ongoing China CARES program Selfreported history blood donation 1995 HIV1 infect CD4 count 200 cells/mmÂ³ ART naive willing notify study staff prior initiate ART Clinical Stage I II World Health Organization ( WHO ) Staging System Willing adhere study followup schedule Willing provide locator information Willing use acceptable form contraception Exclusion Criteria All Participants : Concomitant use ART study Pregnancy Exclusion Criteria Stage II : Plan leave study area 6 month followup period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Former Plasma Donors</keyword>
	<keyword>Commercial Plasma Donors</keyword>
	<keyword>Long-Term Nonprogressors</keyword>
	<keyword>Host Factors</keyword>
	<keyword>Viral Factors</keyword>
	<keyword>HIV</keyword>
</DOC>